These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1335636)

  • 1. Laboratory tests and reference reagents employed in studies of inactivated hepatitis A vaccine.
    Binn LN; MacArthy PO; Marchwicki RH; Sjogren MH; Hoke CH; Burge JR; D'Hondt E
    Vaccine; 1992; 10 Suppl 1():S102-5. PubMed ID: 1335636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of virus strain and antigen dose on immunogenicity and reactogenicity of an inactivated hepatitis A vaccine.
    Goubau P; Van Gerven V; Safary A; Delem A; Knops J; D'Hondt E; André FE; Desmyter J
    Vaccine; 1992; 10 Suppl 1():S114-8. PubMed ID: 1335638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic approaches to assessing the response to inactivated hepatitis A vaccine.
    Lemon SM
    J Hepatol; 1993; 18 Suppl 2():S15-9. PubMed ID: 8182266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the antibody response in humans with a new inactivated hepatitis A vaccine.
    Vidor E; Xueref C; Blondeau C; Bajard A; Francon A; Goudeau A; Peyron F; Brasseur P; Zuckerman A
    Biologicals; 1996 Sep; 24(3):235-42. PubMed ID: 8978923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals.
    Davidson M; Krugman S; Sandman LA
    Vaccine; 1992; 10 Suppl 1():S119-20. PubMed ID: 1335639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of vaccine-induced antibody to hepatitis A virus.
    Wiedermann G; Ambrosch F; André FE; D'Hondt E; Delem A; Safary A
    Vaccine; 1992; 10 Suppl 1():S129-31. PubMed ID: 1335643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody response to nonstructural proteins of hepatitis A virus following infection.
    Robertson BH; Jia XY; Tian H; Margolis HS; Summers DF; Ehrenfeld E
    J Med Virol; 1993 May; 40(1):76-82. PubMed ID: 8390561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactogenicity and immunogenicity of inactivated hepatitis A vaccines.
    Just M; Berger R
    Vaccine; 1992; 10 Suppl 1():S110-3. PubMed ID: 1362031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and laboratory observations following oral or intramuscular administration of a live attenuated hepatitis A vaccine candidate.
    Sjogren MH; Purcell RH; McKee K; Binn L; Macarthy P; Ticehurst J; Feinstone S; Caudill J; See A; Hoke C
    Vaccine; 1992; 10 Suppl 1():S135-7. PubMed ID: 1335645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoprecipitation and virus neutralization assays demonstrate qualitative differences between protective antibody responses to inactivated hepatitis A vaccine and passive immunization with immune globulin.
    Lemon SM; Murphy PC; Provost PJ; Chalikonda I; Davide JP; Schofield TL; Nalin DR; Lewis JA
    J Infect Dis; 1997 Jul; 176(1):9-19. PubMed ID: 9207344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactogenicity and immunogenicity of three different lots of a hepatitis A vaccine.
    Theilmann L; Kallinowski B; Gmelin K; Hofmann F; Scheiermann N; Wohland B; Stickl H; Maiwald H; Moriabadi FK; Bock HL
    Vaccine; 1992; 10 Suppl 1():S132-4. PubMed ID: 1335644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of hepatitis A vaccination schedules on immune response.
    Tilzey AJ; Palmer SJ; Barrow S; Perry KR; Tyrell H; Safary A; Banatvala JE
    Vaccine; 1992; 10 Suppl 1():S121-3. PubMed ID: 1335640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings.
    André FE; D'Hondt E; Delem A; Safary A
    Vaccine; 1992; 10 Suppl 1():S160-8. PubMed ID: 1335652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivated virosome hepatitis A vaccine.
    D'Hondt E; Delem A
    Lancet; 1994 May; 343(8906):1165-6. PubMed ID: 7910259
    [No Abstract]   [Full Text] [Related]  

  • 15. Time course of hepatitis A antibody production after active, passive and active/passive immunisation: the results are highly dependent on the antibody test system used.
    Berger R; Just M; Althaus B
    J Virol Methods; 1993 Aug; 43(3):287-97. PubMed ID: 8408443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of a hepatitis A virus vaccine.
    Flehmig B; Haage A; Pfisterer M
    J Med Virol; 1987 May; 22(1):7-16. PubMed ID: 3035082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis A vaccination: schedule for accelerated immunization.
    Müller R; Chriske H; Deinhardt F; Jilg J; Theilmann L; Hess G; Hofmann F; Hopf U; Stickl H; Maiwald H
    Vaccine; 1992; 10 Suppl 1():S124-5. PubMed ID: 1335641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the immune response of volunteers vaccinated with a killed vaccine against hepatitis A.
    Delem A; Safary A; De Namur F; Hauser P; D'Hondt E
    Vaccine; 1993; 11(4):479-84. PubMed ID: 8385844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An inactivated hepatitis A viral vaccine of cell culture origin.
    Provost PJ; Hughes JV; Miller WJ; Giesa PA; Banker FS; Emini EA
    J Med Virol; 1986 May; 19(1):23-31. PubMed ID: 3009703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of hepatitis A virus vaccine in primates.
    Chaudhary RK; Mo T
    J Infect Dis; 1990 Mar; 161(3):586-7. PubMed ID: 2155977
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.